Team Blitz India
NEW DELHI: Sun Pharmaceutical Industries has said it has entered into a licensing pact with Philogen SpA to commercialise under-development skin cancer drug in Europe, Australia and New Zealand.
The companies have come together to commercialise Philogen’s speciality product Nidlegy, an anti-cancer biopharmaceutical currently in Phase III clinical trials, Sun Pharma said in a statement in May 30.
Philogen, a Swiss-Italian firm, is developing it for the treatment of melanoma and non-melanoma skin cancers.
Under the terms of the agreement, the Mumbai-based drug major will have exclusive rights to commercialise Nidlegy.
The two partner companies will share post-commercialisation economics in about a 50:50 ratio, the drug major said.
